Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Childs Nerv Syst ; 8(2): 81-2, 1992 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-1591751

RESUMEN

We describe two children who after cardiopulmonary arrest developed hypernatremia at the terminal stage. Urinary antidiuretic hormone concentration was very low, indicating central diabetes insipidus. These cases illustrate the necessity of alertness to the development of central diabetes insipidus in patients with severe hypoxic brain damage.


Asunto(s)
Daño Encefálico Crónico/fisiopatología , Diabetes Insípida/fisiopatología , Hipoxia Encefálica/fisiopatología , Vasopresinas/deficiencia , Adolescente , Obstrucción de las Vías Aéreas/fisiopatología , Parálisis Cerebral/fisiopatología , Humanos , Lactante , Masculino , Neurohipófisis/fisiología , Resucitación , Vasopresinas/orina , Equilibrio Hidroelectrolítico/fisiología
5.
Jpn J Antibiot ; 38(3): 553-74, 1985 Mar.
Artículo en Japonés | MEDLINE | ID: mdl-3897599

RESUMEN

A new macrolide antibiotic preparation, TMS-19-Q.O tablet, was used to investigate the efficacy in the treatment of patients with respiratory tract infection, and the results obtained were as follows: Three hundred and seven cases were included in this report, and overall efficacy rate was 76.2%. Especially high clinical effect (86.0%) was observed in the treatment of patients with pneumonia including mycoplasmal pneumonia. Bacteriological effect was 87.5% in 51 cases identified as single infection of Gram-positive cocci and was 48.0% in 34 cases Gram-negative rods infection. Side effects were observed in 11 cases (3.50%): gastrointestinal disorder in 8, eruption in 2 and other in 1. Abnormality in laboratory tests was observed in 23 cases, hepatic disorder in 13, renal disorder in 3 and other laboratory tests in 7. It was considered from the results of clinical and bacteriological efficacy in different dose study that dose of TMS-19-Q should be 600 mg.


Asunto(s)
Antibacterianos/uso terapéutico , Leucomicinas/uso terapéutico , Miocamicina/análogos & derivados , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Adolescente , Adulto , Anciano , Antibacterianos/administración & dosificación , Bronquitis/tratamiento farmacológico , Niño , Ensayos Clínicos como Asunto , Femenino , Humanos , Leucomicinas/administración & dosificación , Masculino , Persona de Mediana Edad , Neumonía por Mycoplasma/tratamiento farmacológico , Infecciones del Sistema Respiratorio/microbiología , Staphylococcus aureus/efectos de los fármacos , Streptococcus pneumoniae/efectos de los fármacos , Comprimidos , Tonsilitis/tratamiento farmacológico
11.
Jpn J Antibiot ; 30(2): 139-44, 1977 Feb.
Artículo en Japonés | MEDLINE | ID: mdl-853569

RESUMEN

Tetracycline is expected to be as effective as erythromycin in the treatment of pneumonia due to Mycoplasma pneumoniae. In this clinical trial 12 cases with pneumonia due to Mycoplasma pneumoniae were given doxycycline (Vibramycin "Pfizer'), a long-acting derivative of tetracycline. Judging from time periods required for defervescence, improvement in symptoms such as cough and disappearance of shadows on chest X-ray, the therapeutic effect of doxycycline was excellent in 8 cases and good in 4 cases.


Asunto(s)
Doxiciclina/uso terapéutico , Infecciones por Mycoplasma/tratamiento farmacológico , Neumonía/tratamiento farmacológico , Adolescente , Adulto , Niño , Preescolar , Doxiciclina/administración & dosificación , Evaluación de Medicamentos , Eritromicina/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mycoplasma/aislamiento & purificación , Neumonía/diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA